STA-4783 in Combination With Paclitaxel and Carboplatin for the Treatment of Chemotherapy Naive Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)

• Status: Completed
• Trial end date: 2005-03-01

Summary

This study is for patients who have Stage IIIb or Stage IV NSCLC and have never had chemotherapy before for their disease. The first phase of the study recently completed and for the second phase of the study patients are randomly assigned to receive either paclitaxel and carboplatin or paclitaxel and carboplatin and study drug (STA 4783). Treatment will be every 3 weeks for 6 cycles.

• Phase: Phase 1/Phase 2

Details

• Lead Sponsor: Synta Pharmaceuticals Corp.
• Treatments: Albumin-Bound Paclitaxel; Carboplatin; Paclitaxel